This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Chloroquine for Treatment of Glioblastoma Multiforme

This study has been completed.
Information provided by:
National Institute of Neurology and Neurosurgery, Mexico Identifier:
First received: September 21, 2005
Last updated: November 17, 2009
Last verified: November 2009
Chloroquine is a strong lysosomotropic and DNA-intercalating agent in experimental studies (Neurosurgical Focus 14(2): February, 2003) and an open-label clinical trial the investigators have demonstrated a strong adjuvant effect of chloroquine on the therapy of malignant gliomas. This study will assess in a randomized, placebo-controlled, double-blind study the effects of chloroquine as adjuvant to the conventional therapy of Glioblastoma Multiforme.

Condition Intervention Phase
Glioblastoma Multiforme Drug: Chloroquine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial

Resource links provided by NLM:

Further study details as provided by National Institute of Neurology and Neurosurgery, Mexico:

Primary Outcome Measures:
  • Survival after surgery

Secondary Outcome Measures:
  • End-point evaluation, survival at two years

Study Start Date: January 2005
Estimated Study Completion Date: August 2005
  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Tumor restricted to one hemisphere of the brain
  • Karnofsky scale >7
  • Histologically confirmed GBM in first or second recurrence or relapse
  • Adequate hematologic, hepatic and renal function
  • Karnofsky performance status score ≥ 70%
  • Life expectancy ≥ 16 weeks

Exclusion Criteria:

  • Gastrointestinal dysfunction
  • Compromised cardiac function
  • Concurrent severe and /or uncontrolled medical conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00224978

National Institute of Neurology and Neurosurgery
Mexico City, Mexico, 14269
Sponsors and Collaborators
National Institute of Neurology and Neurosurgery, Mexico
Principal Investigator: Julio Sotelo, MD National Institute of Neurology and Neurosurgery of Mexico
  More Information

Publications: Identifier: NCT00224978     History of Changes
Other Study ID Numbers: 14/99
Study First Received: September 21, 2005
Last Updated: November 17, 2009

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Chloroquine diphosphate
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antirheumatic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antinematodal Agents
Anthelmintics processed this record on September 19, 2017